IRIS
SICURANZA, ANNA
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 4.457
NA - Nord America 4.381
AS - Asia 2.340
SA - Sud America 403
Continente sconosciuto - Info sul continente non disponibili 192
AF - Africa 132
OC - Oceania 9
Totale 11.914
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.272
RU - Federazione Russa 1.114
IT - Italia 942
SG - Singapore 767
GB - Regno Unito 737
CN - Cina 640
IE - Irlanda 526
BR - Brasile 338
DE - Germania 281
VN - Vietnam 256
SE - Svezia 213
FR - Francia 205
HK - Hong Kong 178
FI - Finlandia 167
UA - Ucraina 96
KR - Corea 92
IN - India 88
BD - Bangladesh 87
ZA - Sudafrica 71
CA - Canada 62
NL - Olanda 34
JP - Giappone 31
AR - Argentina 26
MX - Messico 26
TR - Turchia 26
IQ - Iraq 24
PK - Pakistan 24
PL - Polonia 24
ES - Italia 23
IR - Iran 21
AT - Austria 19
CZ - Repubblica Ceca 16
EG - Egitto 16
SA - Arabia Saudita 14
BE - Belgio 13
ID - Indonesia 11
KE - Kenya 10
CO - Colombia 9
NG - Nigeria 9
UZ - Uzbekistan 9
AU - Australia 8
MA - Marocco 8
MY - Malesia 7
EC - Ecuador 6
PH - Filippine 6
AZ - Azerbaigian 5
BG - Bulgaria 5
CH - Svizzera 5
CI - Costa d'Avorio 5
CL - Cile 5
DZ - Algeria 5
ET - Etiopia 5
JO - Giordania 5
KH - Cambogia 5
LT - Lituania 5
PT - Portogallo 5
BO - Bolivia 4
CR - Costa Rica 4
DO - Repubblica Dominicana 4
GR - Grecia 4
KG - Kirghizistan 4
KZ - Kazakistan 4
NP - Nepal 4
PE - Perù 4
PY - Paraguay 4
UY - Uruguay 4
EE - Estonia 3
HR - Croazia 3
IL - Israele 3
LB - Libano 3
LK - Sri Lanka 3
MD - Moldavia 3
OM - Oman 3
PA - Panama 3
QA - Qatar 3
SK - Slovacchia (Repubblica Slovacca) 3
TT - Trinidad e Tobago 3
VE - Venezuela 3
AE - Emirati Arabi Uniti 2
BY - Bielorussia 2
EU - Europa 2
GE - Georgia 2
HN - Honduras 2
LA - Repubblica Popolare Democratica del Laos 2
LV - Lettonia 2
MN - Mongolia 2
PS - Palestinian Territory 2
TH - Thailandia 2
TN - Tunisia 2
A1 - Anonimo 1
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BH - Bahrain 1
BN - Brunei Darussalam 1
DK - Danimarca 1
GD - Grenada 1
JM - Giamaica 1
KN - Saint Kitts e Nevis 1
LU - Lussemburgo 1
MK - Macedonia 1
Totale 11.716
Salva come PNG Salva come JPEG
Città #
Southend 624
Dallas 561
Dublin 521
Singapore 474
Fairfield 368
Ashburn 358
Moscow 307
San Jose 281
Santa Clara 236
Milan 213
Chandler 185
Hong Kong 170
Munich 163
Beijing 159
Woodbridge 158
Hefei 157
Siena 145
Council Bluffs 140
Seattle 129
Wilmington 125
Helsinki 120
Cambridge 108
Houston 104
Ann Arbor 96
The Dalles 93
New York 92
Seoul 90
Los Angeles 85
Ho Chi Minh City 81
Rome 79
Jacksonville 73
Lauterbourg 70
Florence 64
Princeton 63
Hanoi 61
Johannesburg 61
São Paulo 45
Columbus 33
Dong Ket 31
Nanjing 29
London 28
Shanghai 27
Orem 25
Redondo Beach 25
Tokyo 25
Bengaluru 23
Buffalo 23
Figino 23
Frankfurt am Main 23
Turin 23
Dearborn 22
Chennai 21
Nuremberg 21
Turku 21
Denver 17
San Mateo 17
Toronto 17
Warsaw 17
Boardman 16
Da Nang 16
Düsseldorf 16
San Diego 16
Izmir 15
Portsmouth 15
Chicago 14
Montreal 14
Washington 14
Brooklyn 13
Lappeenranta 13
Stockholm 13
Boston 12
Brussels 12
Messina 12
Mumbai 11
San Francisco 11
Baghdad 10
Bologna 10
Brno 10
Guangzhou 10
Phoenix 10
Vienna 10
Abuja 9
Atlanta 9
Dhaka 9
Poplar 9
Rio de Janeiro 9
Cairo 8
Haiphong 8
Naples 8
Palermo 8
Porto Alegre 8
Tashkent 8
Amsterdam 7
Belo Horizonte 7
Biên Hòa 7
Fremont 7
Hangzhou 7
Mexico City 7
Nanchang 7
Shenyang 7
Totale 7.792
Salva come PNG Salva come JPEG
Nome #
A novel class of oxazepine-based anti-cancer agents induces cell death in primary human CLL cells and efficiently reduces tumor growth in Eμ-TCL1 mice through the JNK/STAT4/p66Shc axis 342
Flow Cytometry Assessment of CD26+ Leukemic Stem Cells in Peripheral Blood: A Simple and Rapid New Diagnostic Tool for Chronic Myeloid Leukemia 320
Circulating CD34+/CD38-/CD26+ Leukemia Stem Cells along Chronic Myeloid Leukemia progression: differences between Chronic, Accelerated and Blast Phase 311
Cardiovascular toxicity in patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors in the real-life practice: Identification of risk factors and the role of prophylaxis 307
Residual peripheral blood CD26+leukemic stem cells in chronic myeloid leukemia patients during TKI therapy and during treatment-free remission 300
Antibody and B-cell responses in myelofibrosis patients after the third doses of mRNA SARS-CoV-2 vaccines 297
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may play a role in increased atherothrombotic events in nilotinib treated chronic myeloid leukemia patients 297
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 296
Atherothrombotic Risk and TKIs Treatment In Chronic Myeloid Leukemia Patients: A Role For Genetic Predisposition and Pro-Inflammatory/Pro-Oxidative Status? 291
Atherothrombotic risk assessment during tyrosine kinase inhibitors treatment in chronic myeloid leukemia patients: new insight? 277
Long-Term Safety of Rapid Daratumumab Infusions in Multiple Myeloma Patients 259
Genetic predisposition and induced pro-inflammatory/pro-oxidative status may explain increased atherothrombotic risk during TKI treatment in chronic myeloid leukemia patients 254
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 250
Real-world experience with decitabine as a first-line treatment in 306 elderly acute myeloid leukaemia patients unfit for intensive chemotherapy 250
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 246
A case of acquired factor XIII deficiency secondary to plasmablastic lymphoma 240
Study of gene polymorphisms as predictors of treatment efficacy and toxicity in patients with indolent non-hodgkin lymphomas and mantle cell lymphoma receiving bendamustine and rituximab 239
Peptide vaccines for hematological malignancies: a missed promise? 236
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 229
Overview of Anti-SARS-CoV-2 Immune Response Six Months after BNT162b2 mRNA Vaccine 227
Antibody response in myelofibrosis patients after three doses of mRNA SARS-CoV-2 vaccine 224
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 218
First reported case of secondary mixed phenotype acute leukemia after multiple myeloma 211
Cladribine Efficacy in a Patient with Hairy Cell Leukemia and Severe Renal Insufficiency 204
Prognostic significance of lymphocyte/monocyte count and neutrophil/lymphocyte count in peripheral T cell lymphoma 201
The third dose of mRNA SARS-CoV-2 vaccines enhances the spike-specific antibody and memory B cell response in myelofibrosis patients 199
Hodgkin lymphoma in the elderly: new perspectives and a 10-year monocenter real-life experience 198
Prognostic impact of tumor-associated macrophages, lymphocyte-to-monocyte and neutrophil-to-lymphocyte ratio in diffuse large B-cell lymphoma 195
Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies 194
Minimal residual disease in multiple myeloma: State of the art and applications in clinical practice 192
Prospective monitoring of Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation: the fate of Peripheral Blood CD26+ Leukemia Stem Cells 186
Fludarabine, high-dose cytarabine and idarubicin-based induction may overcome the negative prognostic impact of FLT3-ITD in NPM1 mutated AML, irrespectively of FLT3-ITD allelic Burden 186
Drug resistance and minimal residual disease in multiple myeloma 166
Efficacy and safety of ruxolitinib for Covid-19 related acute respiratory distress syndrome in a patient with blastic plasmacytoid dendritic cell neoplasm (leukemic variant) 166
The slower antibody response in myelofibrosis patients after two doses of MRNA sars-COV-2 vaccine calls for a third dose 163
Pro-Inflammatory and Pro-Oxidative Changes During Nilotinib Treatment in CML Patients: Results of a Prospective Multicenter Front-Line TKIs Study (KIARO Study) 162
Peripheral Blood CD26+ Leukemia Stem Cells Monitoring in Chronic Myeloid Leukemia Patients from Diagnosis to Response to TKIs: Interim Results of a Multicenter Prospective Study (PROSPECTIVE FLOWERS) 161
Longitudinal immunogenicity cohort study of SARS-CoV-2 mRNA vaccines across individuals with different immunocompromising conditions: heterogeneity in the immune response and crucial role of Omicron-adapted booster doses 161
DART4MM: Daratumumab as Consolidation Therapy in Patients who Already Achieved Optimal Response/MRD Positivity by Next Generation Flow (NGF): Preliminary Results of a Phase 2 Multicenter Study 159
Long-term mortality rate for cardiovascular disease in 656 chronic myeloid leukaemia patients treated with second- and third-generation tyrosine kinase inhibitors 158
Minimal Residual Disease Detection at RNA and Leukemic Stem Cell (LSC) Levels: Comparison of RT-qPCR, d-PCR and CD26+ Stem Cell Measurements in Chronic Myeloid Leukemia (CML) Patients in Deep Molecular Response (DMR) 157
Favorable outcome of chronic myeloid leukemia co-expressing e13a2 and e14a2 transcripts, treated with nilotinib 147
The prognostic role of gene polymorphisms in patients with indolent non-Hodgkin lymphomas and mantle-cell lymphoma receiving bendamustine and rituximab: results of the 5-year follow-up study 146
Prognostic value of CD47 overexpression measured by flow cytometry in acute myeloid leukemia 143
Tumor-Associated Macrophages in Multiple Myeloma: Key Role in Disease Biology and Potential Therapeutic Implications 142
Infectious complications after induction chemotherapy with FLAI(E) in newly diagnosed AML, omitting antibacterial prophylaxis 141
Long-term CR Multiple Myeloma Patients Show Cured or MGUS-like Minimal Residual Disease Pattern by Next Generation Flow 141
Prospective Monitoring of Peripheral Blood CD26+ Leukemia Stem Cells in Chronic Myeloid Leukemia Patients from Time of TKI Discontinuation 139
Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy 139
Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors 138
Are small lymphocytic lymphoma and chronic lymphocytic leukemia the same disease? The unsolved dilemma 135
Minimal Residual Disease Significance in Multiple Myeloma Patients Treated with Anti-CD38 Monoclonal Antibodies 135
CD26/DPP-4 in Chronic Myeloid Leukemia 132
Venetoclax in association with decitabine as effective bridge to transplant in a case of relapsed early T-cell lymphoblastic leukemia 126
The role of tumor-associated macrophages in hematologic malignancies 120
Intensive Fludarabine, High Dose Cytarabine and Idarubicin-Based Induction for Younger NPM1-Mutated AML Patient: Overcoming the Negative Prognosis of FLT3-ITD Mutation 109
Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib 108
Unravelling a clinical role of peripheral blood leukemia stem cells at diagnosis in chronic myeloid leukemia patients: Final results of prospective FLOWERS study 95
Low rate of infectious mortality omitting fluoroquinolone prophylaxis in high-risk hematological patients, a single centre experience 70
The biology of chronic myeloid leukemia: an overview of the new insights and biomarkers 62
VEXAS syndrome and cancer: Insights about a possible “Tip of the Iceberg”. Ambidirectional data from the international AIDA network registries 54
Tracking leukemic residuals: dissecting the inverse relationship between CD26+ stem cells and extracellular BCR::ABL1 transcript in Chronic Myeloid Leukemia (CML) 49
Clinical and laboratory markers to distinguish VEXAS from Schnitzler's syndrome: data from the AIDA network registries 47
Reply to “Peripheral blood CD26+ leukemic stem cells in chronic myeloid leukemia and tyrosine kinase inhibitor response: Questions remain!” 34
MRD-negative conversion with daratumumab monotherapy in newly diagnosed multiple myeloma patients in ≥VGPR/MRD-positive after first-line therapy: Final analysis of the open-label, single-arm multicentric phase 2 trial DART4MM 33
Totale 11.914
Salva come PNG Salva come JPEG
Categoria #
all - tutte 38.173
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 38.173
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022567 0 71 33 55 39 18 26 18 42 41 108 116
2022/2023834 42 94 106 82 60 130 30 86 76 11 94 23
2023/20241.026 31 32 95 62 53 246 330 23 12 41 23 78
2024/20251.937 35 61 215 99 205 134 104 129 211 116 209 419
2025/20264.980 337 590 480 662 1.044 181 471 130 148 324 152 461
2026/2027349 201 148 0 0 0 0 0 0 0 0 0 0
Totale 11.914